Clinical Use and Pathogenetic Basis of Laboratory Tests for the Evaluation of Primary Arterial Hypertension

2005 ◽  
Vol 42 (5-6) ◽  
pp. 393-452 ◽  
Author(s):  
Teresa M. Seccia ◽  
Gian Paolo Rossi
Keyword(s):  
Arterial Hypertension ◽  
Laboratory Tests ◽  
Clinical Use ◽  
Primary Arterial Hypertension

Critical limb ischaemia in diabetes: definition, assessment, prognosis

VASA ◽  
2001 ◽  
Vol 30 (Supplement 58) ◽  
pp. 21-27
Author(s):  
Luther
Keyword(s):  
Diabetic Foot ◽  
Laboratory Tests ◽  
Critical Limb Ischaemia ◽  
Limb Ischaemia ◽  
Clinical Use ◽  
Arterial Reconstruction ◽  
Arterial Circulation ◽  
Diabetic Foot Disease ◽  
Foot Disease ◽  
Fontaine Classification

In diabetic foot disease, critical limb ischaemia (CLI) cannot be precisely described using established definitions. For clinical use, the Fontaine classification complemented with any objective verification of a reduced arterial circulation is sufficient for decision making. For scientific purposes, objective measurement criteria should be reported. Assessment of CLI should rely on the physical examination of the limb arteries, complemented by laboratory tests like the shape of the PVR curve at ankle or toe levels, and arteriography. The prognosis of CLI in diabetic foot disease depends on the success of arterial reconstruction. The best prognosis for the patients is with a preserved limb. Reconstructive surgery is the best choice for the majority of patients.

PO-0031 Preferable Disorders In The Children With Primary Arterial Hypertension Assotiated With Endothelial Disfunction

2014 ◽  
Vol 99 (Suppl 2) ◽  
pp. A260.3-A261
Author(s):  
OM Horlenko ◽  
VI Rusyn ◽  
NV Sochka ◽  
OO Boldizhar ◽  
OV Debreceni ◽  
...  
Keyword(s):  
Arterial Hypertension ◽  
Primary Arterial Hypertension

scholarly journals The relationship between plasma renin activity and serum lipid profiles in patients with primary arterial hypertension

2018 ◽  
Vol 19 (4) ◽  
pp. 147032031881002 ◽  
Author(s):  
Tomasz Pizoń ◽  
Marek Rajzer ◽  
Wiktoria Wojciechowska ◽  
Małgorzata Wach-Pizoń ◽  
Tomasz Drożdż ◽  
...  
Keyword(s):  
Plasma Renin Activity ◽  
Arterial Hypertension ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Plasma Renin ◽  
Serum Levels ◽  
Renin Activity ◽  
Serum Aldosterone ◽  
Primary Arterial Hypertension ◽  
Aldosterone To Renin Ratio

Introduction: The aim of the study was to evaluate clinical and biochemical differences between patients with low-renin and high-renin primary arterial hypertension (AH), mainly in reference to serum lipids, and to identify factors determining lipid concentrations. Materials and methods: In untreated patients with AH stage 1 we measured plasma renin activity (PRA) and subdivided the group into low-renin (PRA < 0.65 ng/mL/h) and high-renin (PRA ⩾ 0.65 ng/mL/h) AH. We compared office and 24-h ambulatory blood pressure, serum aldosterone, lipids and selected biochemical parameters between subgroups. Factors determining lipid concentration in both subgroups were assessed in regression analysis. Results: Patients with high-renin hypertension ( N = 58) were characterized by higher heart rate ( p = 0.04), lower serum sodium ( p < 0.01) and aldosterone-to-renin ratio ( p < 0.01), and significantly higher serum aldosterone ( p = 0.03), albumin ( p < 0.01), total protein ( p < 0.01), total cholesterol ( p = 0.01) and low-density lipoprotein cholesterol (LDL-C) ( p = 0.04) than low-renin subjects ( N = 39). In univariate linear regression, only PRA in the low-renin group was in a positive relationship with LDL-C ( R2 = 0.15, β = 1.53 and p = 0.013); this association remained significant after adjustment for age, sex, and serum albumin and aldosterone concentrations. Conclusions: Higher serum levels of total and LDL-C characterized high-renin subjects, but the association between LDL-C level and PRA existed only in low-renin primary AH.

scholarly journals Current Drugs with Potential for Treatment of COVID-19: A Literature Review

2020 ◽  
Vol 23 (1) ◽  
pp. 58-64 ◽  
Author(s):  
Md Insiat Islam Rabby
Keyword(s):  
Clinical Trial ◽  
Severe Acute Respiratory Syndrome ◽  
Laboratory Tests ◽  
Literature Search ◽  
Treatment Process ◽  
Clinical Use ◽  
Animal Trial ◽  
Chinese Drugs ◽  
Inflammatory Drugs ◽  
Traditional Chinese Drugs

Purpose: SARS-CoV-2 first emerged in China in December 2019 and rapidly spread worldwide. No vaccine or approved drug is available to eradicate the virus, however, some drugs that are indicated for other afflictions seems to be potentially beneficial to treat the infection albeit without unequivocal evidence.   The aim of this article is to review the published background on the effectiveness of these drugs against COVID-19 Methods: A thorough literature search was conducted on recently published studies which have published between January 1 to March 25, 2020. PubMed, Google Scholar and Science Direct databases were searched Results: A total 22 articles were found eligible. 8 discuss about treatment outcomes from their applied drugs during treatment of COVID-19 patients, 4 report laboratory tests, one report animal trial and other 9 articles discuss recommendations and suggestions based on the treatment process and clinical outcomes of other diseases such as malaria, ebola, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). The data and/or recommendations are categorized in 4 classes: (a) anti-viral and anti-inflammatory drugs, (b) anti-malaria drugs, (c) traditional Chinese drugs and (d) other treatments/drugs. Conclusion: All examined treatments, although potentiality effective against COVID-19, need either appropriate drug development or clinical trial to be suitable for clinical use.

Sign in / Sign up

Export Citation Format

Share Document